- Home
- CADL vs INM Comparison
CADL vs INM Comparison
Compare CADL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- INM
- Stock Information
- Founded
- CADL 1999
- INM 1981
- Country
- CADL United States
- INM Canada
- Employees
- CADL N/A
- INM N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- INM Health Care
- Exchange
- CADL Nasdaq
- INM Nasdaq
- Market Cap
- CADL 339.8M
- INM 5.0M
- IPO Year
- CADL 2021
- INM N/A
- Fundamental
- Price
- CADL $5.60
- INM $2.15
- Analyst Decision
- CADL Strong Buy
- INM
- Analyst Count
- CADL 6
- INM 0
- Target Price
- CADL $20.33
- INM N/A
- AVG Volume (30 Days)
- CADL 911.4K
- INM 120.8K
- Earning Date
- CADL 11-13-2025
- INM 11-13-2025
- Dividend Yield
- CADL N/A
- INM N/A
- EPS Growth
- CADL N/A
- INM N/A
- EPS
- CADL N/A
- INM N/A
- Revenue
- CADL N/A
- INM $4,942,633.00
- Revenue This Year
- CADL N/A
- INM N/A
- Revenue Next Year
- CADL N/A
- INM N/A
- P/E Ratio
- CADL N/A
- INM N/A
- Revenue Growth
- CADL N/A
- INM 7.50
- 52 Week Low
- CADL $3.79
- INM $1.72
- 52 Week High
- CADL $14.60
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- CADL 48.96
- INM 45.46
- Support Level
- CADL $5.26
- INM $2.04
- Resistance Level
- CADL $6.27
- INM $2.26
- Average True Range (ATR)
- CADL 0.47
- INM 0.14
- MACD
- CADL -0.04
- INM -0.01
- Stochastic Oscillator
- CADL 32.61
- INM 21.74
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.